Goldline Pharmaceutical Limited (BOM:544759)
India · Delayed Price · Currency is INR 45.25
+2.29 (5.33%)
At close: Jun 5, 2026
Goldline Pharmaceutical Revenue
In the fiscal year ending March 31, 2025, Goldline Pharmaceutical had annual revenue of 280.56M INR with 19.05% growth.
Revenue
280.56M
Revenue Growth
+19.05%
P/S Ratio
1.55
Revenue / Employee
2.83M
Employees
99
Market Cap
434.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 280.56M | 44.90M | 19.05% |
| Mar 31, 2024 | 235.66M | 37.18M | 18.73% |
| Mar 31, 2023 | 198.48M | -41.62M | -17.33% |
| Mar 31, 2022 | 240.11M | 21.15M | 9.66% |
| Mar 31, 2021 | 218.95M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Centuple Global | 5.74B |
| Rama Vision | 1.59B |
| Novelix Pharmaceuticals | 1.32B |
| Dipna Pharmachem | 1.07B |
| Medico Intercontinental | 853.55M |
| Medistep Healthcare | 708.31M |
| Chandra Bhagat Pharma | 493.95M |
| Constronics Infra | 486.14M |